November 8 - 10, 2018

San Diego, CA

 

Accreditation

CONTINUING MEDICAL EDUCATION 

 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 25 contact hours (a maximum of 19 hours for the general sessions and a maximum of 6 hours for the workshops). Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

California Board of Registered Nursing

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 25 contact hours.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 25 AMA PRA Category 1 Credits™  (a maximum of 19 credits for the general sessions and a maximum of 6 credits for the workshops).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants Credit Designation
The American Academy of Physician’s Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME.

Overall Learning Objectives:
After completing this live activity, participants should be able to:
• Analyze disease patterns and apply pattern recognition to the clinical evaluation and differential diagnoses in patients with respiratory disease, allergy and cardiovascular disease (CV).
• Integrate into daily practice evidence-based recommendations for the clinical management of respiratory disease, allergy and CVD, including aggressive treatment and treatment-to-target strategies.
• Evaluate the safety and efficacy of pharmacotherapy in the treatment of chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis, sinusitis, hypertension, dyslipidemia, thyroid and heart, renal disease, coronary artery diseases (CAD) and peripheral arterial disease (PAD).
• Discuss the currently available and emerging medications that target established and newly recognized pathways in the pathogenesis of respiratory disease, allergy and CVD.
• Incorporate new therapies in appropriately selected patients.
• Provide evidence-based patient education on treatment options, use of inhalers and breathing aids, and the role of home care.
• Review routine practice protocols for use of the most appropriate outcomes measures
• Formulate evidence-based lifestyle management plans incorporating updated recommendations for patients with respiratory disease, allergy and CVD.
• Develop individualized strategies for respiratory, allergy and cardiovascular therapy.
• Recognize the need for referral to a pulmonologist, allergist or cardiologist and understand the role of appropriate handoff, documentation and communication in the referral process.
 

Learning Objectives

Incorporating the New Hypertension Guidelines into Your Clinical Practice
Leslie L. Davis, PhD, RN, ANP-BC, FAANP, FPCNA, FAHA
1. Review the new (2017) treatment guidelines for adults with hypertension (HTN).
2. Discuss the rationale to the revised blood pressure goals and implications for new classification and definition of HTN.
3. Review the main pharmacologic agents that should be used to treat HTN in adults.
4. Review rationale for using which particular classes of medications in patients with specific comorbid conditions.

Hypertension and Renal Disease: It Really Isn’t that Difficult, Trust me!
Denise Link, MPAS, PA-C
1. Explain how CKD can lead to secondary and uncontrolled HTN.
2. Recognize how uncontrolled BP can worsen CKD and albuminuria prognosis.
3. Determine the proper dosing of thiazide and loop diuretics based upon level of CKD stage, albuminuria and patient compliance.
4. Discuss the latest BP guidelines based upon age and comorbidities such as CKD and presence of albuminuria.
5. I illustrate how patient education of their diseases, medications and lifestyle will facilitate in achieving BP management.

Asthma: Guideline-Informed Practice
Mary Lou Hayden, RN, MS, FNP-BC, AE-C
1.Discuss presenting signs and symptoms of asthma.
2. Describe objectives and diagnostic testing for asthma.
3. Apply guidelines-directed pharmacotherapy to level of asthma signs and symptoms.

Severe and Difficult Asthma:  Differential Diagnosis, Phenotypes, Genotypes, and Precision Medicine for the Primary Care Practitioner
Concettina Tolomeo, DNP, MSN, BSN
1.Define severe persistent asthma.
2. Identify at least two asthma co-morbidities.
3. Recognize at least two tests used to assess asthma phenotype.
4. Describe how phenotype identification may guide personalized asthma management.
5. List at least two pharmacologic therapies for severe asthma.
6. List at least two non-pharmacologic therapies.

Women and Heart Disease: Symptom Recognition and Moving to Care                                     
Leslie L. Davis, PhD, RN, ANP-BC, FAANP, FPCNA, FAHA
1. Discuss traditional and emerging risk factors that lead to ischemic heart disease (IHD) in women.
2. Review the pathophysiological differences in IHD in women versus men.
3. Distinguish between typical symptom presentations for women with IHD as compared to those of men. 
4. Discuss current recommendations for primary and secondary prevention of IHD in women. 
5. Identify four medication classes that are considered “core post-myocardial infarction medications” in order to reduce morbidity and mortality and improve quality of life in women who have had a heart attack. 
6. Apply knowledge to case scenarios of women at risk or with IHD.

                        
Peripheral Arterial Disease (PAD) Guidelines: How Should We Be Adapting Them to Our Practice?  
Midge Bowers, DNP, FNP-BC, AACC, CHSE, FAANP.
1.Discuss the scope of the 2016 PAD Guidelines.
2. Describe the clinical assessment for PAD.
3. Identify diagnostic and screening testing strategies.
4. Discuss medical therapy for the patient with PAD.
5. Apply the PAD guidelines to clinical scenarios.

Allergic March
Part 1. Atopic Dermatitis:  Diagnosis and Management from Moisturizers to Newly Approved Biologics

Megan Ott Lewis, MSN, RN, CPNP
 1. Participants will be able to discuss current guidelines for stepwise management of atopic dermatitis.
2. Participants will be able to discuss the role of topical steroids, calcineurin inhibitors and PDE4 inhibitors.  
3. Participants will be able to demonstrate the role of non-pharmacologic therapies, including wet wraps, bleach baths and eczema management plans.

Part 2. Food Allergy: Prevalence, Prevention, Diagnosis, and Management
Megan Ott Lewis, MSN, RN, CPNP
1. Participants will be able to discuss recent studies that have shown benefit in early introduction of food allergens.
2. Participants will identify who is at risk for developing food allergies and steps that should be taken to help reduce their risks.
3. Participants will be able to discuss the current way to diagnose and manage food allergies.

Part 3. Allergic Rhinitis: Giving the Nose its Due Respect
Megan Ott Lewis, MSN, RN, CPNP
1.Participants will be able to describe stepwise management to treating allergic rhinitis.
2.Participants will discuss possible allergic triggers in patient environments that can exacerbate symptoms.
3.Participants will describe treatment options, including nasal steroids, saline rinses and sublingual and subcutaneous immunotherapy.

Anaphylaxis: Recognizing, Treating and Controversies
Mary Lou Hayden, RN, MS, FNP-BC, AE
1.Discuss presenting signs and symptoms of anaphylaxis.
2.Discuss evidence-based treatment options.
3.Discuss controversies in diagnosis and management of anaphylaxis.

COPD: Updated 2018 GOLD Guidelines
Gabriel Ortiz, MPAS, PA-C, DFAAPA
1.Discuss the updated 2018 GOLD guidelines for COPD.
2. Discuss the prevalence, risk factors and prevention of COPD.
3. Describe the diagnosis and prevention of COPD.
4. Explain pharmacologic and non-pharmacologic treatments of COPD.

Pharmacology: Testing your Knowledge – An Interactive Presentation                              
Daniel Thomas Thibodeau, MHP, PA-C, DFAAPA
1. Recognize different cardiovascular medications used in typical disease states.
2. Identify the most common indications used for these medications.
3. Determine the potential adverse effects and potential pitfalls for utilizing these drugs.
4. Select to avoid using some of these medications in harmful conditions.

Cardiac Cases & Lessons Learned: How Not to Lose Your License
John G. McGinnity, MS, PA-C, DFAAPA
1.Focus a patient interview and physical examination to assist with the development of a differential diagnosis.
2. Review cardiac conditions that may be present with significant consequences if not timely diagnosed.
3. Review the treatment guidelines and latest evidence associated with each condition.

Chronic Sinusitis: Guidelines-based Treatment Approaches
Brian Bizik, PA-C
1. Discover the prevalence of chronic sinusitis and discuss which acute sinusitis patterns may lead to a chronic sinusitis diagnosis.
2. Determine the criteria for the accurate and timely diagnosis of chronic sinusitis.
3. Discern which patient types need radiographic imaging.
4. Review the current guidelines for the treatment of chronic sinusitis and strategies for the prevention of symptoms. 

Lower Respiratory Infections in the Primary Care Office: Pneumonia and Bronchitis
Honor Hightshue, FNP
1.Identify the distinguishing clinical features of acute bronchitis.
2. Identify the distinguishing clinical factures of community-acquired pneumonia (CAP) and when to order imaging.
3. Identify guideline-based antibiotic treatment of CAP.
4. Identify strategies to delay prescribing antibiotic treatment for acute bronchitis.
5. Identify effective symptomatic and supportive treatment for acute bronchitis.

A Global Approach to Coronary Artery Diseases (CAD) and Improving Outcomes    
Daniel Thomas Thibodeau, MHP, PA-C, DFAAPA
1. Identify the risk measures for patients with coronary artery disease.
2. Determine the first-line treatment options for this patient population.
3. Discuss how to initiate treatment in a stepwise fashion.
4. Identify any potential adverse effects that may occur with treatment options.
5. Measure outcomes that are used in assessing success of treatment.

Understanding Ways to Improve Survival in a Coronary Artery Diseases (CAD) Patient with Diabetes
Christine Kessler MN, ANP-BC, CNS, BC-ADM, FAANP
1.Characterize type 2 diabetes as a cardiovascular risk factor.
2. Discuss key aspects of care for a patient with type 2 diabetes.
3. Compare efficacy, safety and cardiovascular benefits of current diabetes medications.
4. Identify appropriate glycemic targets for patients with diabetes and CV disease.

The Thyroid and the Heart: How to Avoid a Clinical Catastrophe
Christine Kessler MN, ANP-BC, CNS, BC-ADM, FAANP
1.Describe the cardiovascular effects of thyroid hormone.
2. List the cardiovascular sequela and clinical manifestations of overt & subclinical hypo- & hyperthyroidism.
3. Identify assessment and treatment priorities in managing patients with hypo- & hyperthyroidism, especially as it pertains to cardiovascular dysfunction.

Finally, Some Real Options to Control Severe Dyslipidemia
John G. McGinnity, MS, PA-C, DFAAPA
1.Discuss the impact of dyslipidemia on cardiovascular health and patient outcomes.
2. Compare and contrast recommendations and guidelines on treatment of dyslipidemia.
3. Develop optimal treatment strategies in dyslipidemia to improve patient outcomes.
4. Discuss newly approved agents for treatment of dyslipidemia.

Recurrent Infections: Is it Current Viral Exposures or Something More Sinister, Primary Immune Deficiency
Brian Bizik, PA-C
1. Determine the common presentation scenarios of Primary Immunodeficiency and when to suspect more than just frequent infections in your patient. 
2. Review the diagnostic and laboratory evaluations needed to determine if PID is present. 
3. Decide when a referral to a specialist is warranted and what patient outcomes are likely to be with appropriate treatment. 
4. Review the Joint Task Force Practice Parameter for the Diagnosis and Management of PID from the AAAAI and the American College of Allergy, Asthma and Immunology. 

Chronic Cough: Is the Source the Upper Airway, Lower Airway, Gut, Heart or in the Head
Honor Hightshue, FNP
1.Discuss differential diagnoses of chronic cough.
2. Discuss subjective and objective findings to utilize in diagnosing chronic cough.
3. Discuss evidenced-based treatment of chronic cough.

Follow Us

Jointly Provided By

In Association With